A multicentre UK study of adults with inflammatory bowel disease (IBD) compared with healthy individuals as controls assessed the effect of several immunosuppressive IBD treatments on immune responses to SARS-CoV-2 vaccines. Participants who had all received two doses of the Pfizer–BioNTech BNT162b2, the Moderna mRNA-1273 or the AstraZeneca–University of Oxford ChAdOx1 nCoV-19 vaccines were recruited (n = 483), and antibody responses were measured 53–92 days after second vaccine dose. In patients with IBD, the antibody response of SARS-CoV-2 vaccines did vary according to immunosuppressive drug regimen and was lower in patients receiving infliximab, infliximab plus thiopurines, or tofacitinib than in healthy individuals as controls.
References
Original article
Alexander, J. L. et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol. Hepatol. https://doi.org/10.1016/S2468-1253(22)00005-X (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity. Nat Rev Gastroenterol Hepatol 19, 216 (2022). https://doi.org/10.1038/s41575-022-00603-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00603-z
